{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:50:10Z","timestamp":1788364210064,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01038-6","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:57:19Z","timestamp":1769075839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Durvalumab-associated membranous nephropathy: a case report and brief literature review"],"prefix":"10.1007","volume":"15","author":[{"given":"Ryotaro","family":"Mizoguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Sakakima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"11","key":"1038_CR1","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","volume":"39","author":"EB Barbir","year":"2024","unstructured":"Barbir EB, Kitchlu A, Herrmann SM. Immune checkpoint inhibitor\u2013associated nephritis\u2014treatment standard. Nephrol Dial Transplant. 2024;39(11):1785\u201398. https:\/\/doi.org\/10.1093\/ndt\/gfae184.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1038_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","volume":"6","author":"A Kitchlu","year":"2021","unstructured":"Kitchlu A, Jhaveri KD, Wadhwani S, et al. A systematic review of immune checkpoint inhibitor\u2013associated glomerular disease. Kidney Int Rep. 2021;6(1):66\u201377. https:\/\/doi.org\/10.1016\/j.ekir.2020.10.002.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"1038_CR3","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ekir.2023.06.001","volume":"8","author":"R Benyahia","year":"2023","unstructured":"Benyahia R, Lazareth H, Flahault A, et al. Membranous nephropathy after exposure to immune checkpoint inhibitors: case reports and mini-review of the literature. Kidney Int Rep. 2023;8(9):1892\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2023.06.001.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"1038_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s13730-021-00645-3","volume":"11","author":"K Wakabayashi","year":"2022","unstructured":"Wakabayashi K, Yamamoto S, Hara S, et al. Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma. CEN Case Rep. 2022;11(2):171\u20136. https:\/\/doi.org\/10.1007\/s13730-021-00645-3.","journal-title":"CEN Case Rep"},{"key":"1038_CR5","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/sj.ki.5001790","volume":"70","author":"C Lefaucheur","year":"2006","unstructured":"Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, et al. GN-PROGRESS study group: membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006;70:1510\u20137. https:\/\/doi.org\/10.1038\/sj.ki.5001790.","journal-title":"Kidney Int"},{"issue":"8","key":"1038_CR6","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s40620-023-01751-4","volume":"36","author":"S Ai","year":"2023","unstructured":"Ai S, Yan X, Zhao X, et al. Malignancy-associated membranous nephropathy: focus on diagnosis and treatment. J Nephrol. 2023;36(8):2355\u201363. https:\/\/doi.org\/10.1007\/s40620-023-01751-4.","journal-title":"J Nephrol"},{"issue":"6","key":"1038_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/modpathol.2012.237","volume":"26","author":"CC Huang","year":"2013","unstructured":"Huang CC, Lehman A, Albawardi A, et al. IgG subclass staining in membranous glomerulonephritis indicates subclass differences across primary vs secondary disease. Mod Pathol. 2013;26(6):799\u2013805. https:\/\/doi.org\/10.1038\/modpathol.2012.237.","journal-title":"Mod Pathol"},{"issue":"5","key":"1038_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/PAS.0000000000000605","volume":"40","author":"J Hemminger","year":"2016","unstructured":"Hemminger J, Nadasdy G, Satoskar A, et al. IgG subclass staining in routine renal biopsy material. Am J Surg Pathol. 2016;40(5):617\u201326. https:\/\/doi.org\/10.1097\/PAS.0000000000000605.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1038_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","volume":"7","author":"O Mamlouk","year":"2019","unstructured":"Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: glomerular diseases. J Immunother Cancer. 2019;7(1):2. https:\/\/doi.org\/10.1186\/s40425-018-0478-8.","journal-title":"J Immunother Cancer"},{"key":"1038_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/23993693211004612","volume":"5","author":"M Bonilla-Fuentes","year":"2021","unstructured":"Bonilla-Fuentes M, Mart\u00ednez-Pis\u00f3n L, Mart\u00ednez-C\u00e1ceres E, et al. Phospholipase A2 receptor antibody-mediated membranous nephropathy associated with cemiplimab: a case report. J Onco-Nephrol. 2021;5:27\u201330. https:\/\/doi.org\/10.1177\/23993693211004612.","journal-title":"J Onco-Nephrol"},{"key":"1038_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.619147","volume":"12","author":"M Chen","year":"2021","unstructured":"Chen M, Zhang L, Zhong W, Zheng K, Ye W, Wang M. Case report: THSD7A-positive membranous nephropathy caused by tislelizumab in a lung cancer patient. Front Immunol. 2021;12:619147. https:\/\/doi.org\/10.3389\/fimmu.2021.619147.","journal-title":"Front Immunol"},{"issue":"1","key":"1038_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/23993693221125487","volume":"7","author":"D Oleas","year":"2022","unstructured":"Oleas D, Saurina A. Case report: anti-PLA2R positive membranous nephropathy associated with atezolizumab. J Onco-Nephrol. 2022;7(1):22\u20136. https:\/\/doi.org\/10.1177\/23993693221125487.","journal-title":"J Onco-Nephrol"},{"issue":"3","key":"1038_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ekir.2022.12.018","volume":"8","author":"A Nimkar","year":"2023","unstructured":"Nimkar A, Mehtabdin K, Wang X, Jhaveri KD. Pembrolizumab-associated NELL-1 membranous nephropathy. Kidney Int Rep. 2023;8(3):676\u20139. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.018.","journal-title":"Kidney Int Rep"},{"key":"1038_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898811","volume":"13","author":"P Ratanasrimetha","year":"2022","unstructured":"Ratanasrimetha P, Reddy VD, Kala J, et al. Immune checkpoint inhibitor\u2013associated membranous nephropathy in renal cell carcinoma\u2014successful treatment with rituximab. Front Immunol. 2022;13:898811. https:\/\/doi.org\/10.3389\/fimmu.2022.898811.","journal-title":"Front Immunol"},{"key":"1038_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s13730-022-00750-x","volume":"12","author":"A Hoshina","year":"2023","unstructured":"Hoshina A, Endo S. Anti-glomerular basement membrane glomerulonephritis concurrent with membranous nephropathy and acute tubular interstitial nephritis in a lung cancer patient treated with pembrolizumab. CEN Case Rep. 2023;12:230\u20136. https:\/\/doi.org\/10.1007\/s13730-022-00750-x.","journal-title":"CEN Case Rep"},{"issue":"1","key":"1038_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/ckj\/sfz074","volume":"14","author":"Y Kim","year":"2021","unstructured":"Kim Y. Relapse of membranous nephropathy with cancer immunotherapy. Clin Kidney J. 2021;14(1):418\u201320. https:\/\/doi.org\/10.1093\/ckj\/sfz074.","journal-title":"Clin Kidney J"},{"issue":"1","key":"1038_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","volume":"8","author":"A Meraz-Mu\u00f1oz","year":"2020","unstructured":"Meraz-Mu\u00f1oz A, Amir E, Ng P, Avila-Casado C, Ragobar C, Chan C, et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020;8(1):e000467. https:\/\/doi.org\/10.1136\/jitc-2019-000467.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"1038_CR18","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1016\/j.ekir.2021.08.021","volume":"6","author":"MG Toda","year":"2021","unstructured":"Toda MG, Fujii K, Kato A, Yoshifuji A, Komatsu M, Amino Y, et al. Minimal change disease associated with durvalumab. Kidney Int Rep. 2021;6(10):2733\u20134. https:\/\/doi.org\/10.1016\/j.ekir.2021.08.021.","journal-title":"Kidney Int Rep"},{"issue":"10","key":"1038_CR19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.70960","volume":"16","author":"K Hemapriya","year":"2024","unstructured":"Hemapriya K, Balasubramanian S, Gunabooshanam B, Ponneyinchelvi AS, Pavithra V, Elumalai RP. A clinicopathological analysis of membranous nephropathy and its correlation with the immunohistochemical expression of phospholipase A2 receptor (PLA2R) in renal biopsies in a tertiary care center. Cureus. 2024;16(10):e70960. https:\/\/doi.org\/10.7759\/cureus.70960.","journal-title":"Cureus"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01038-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:57:22Z","timestamp":1769075842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01038-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01038-6","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflicts of interest exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Written informed consent for publication of clinical details and images was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"30"}}